- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06105138
Cannabidiol Effects on Blood Alcohol Level and Intoxication
Exploring the Effects of Acute Cannabidiol Administration on Blood Alcohol Level and Intoxication in Adult Human Subjects
Study Overview
Status
Conditions
Detailed Description
Cannabidiol (CBD), is commonly found in the cannabis plant and has shown promise in treating alcohol use disorders (AUD). In this within-subjects, placebo-controlled, crossover study, the investigators explored the effects of two doses (200mg and 30mg) of plant-based CBD (compared to placebo CBD) on blood alcohol level, subjective effects of alcohol, craving and cognition over the course 4 hours after subjects consume a standardized dose of alcohol.
This pilot study was conducted at Colorado State University and volunteers were recruited from the local community. 36 individuals completed at least 1 study session and 22 completed all three sessions. At each session they received either placebo 30mg oral CBD or 200mg oral CBD prior to being given a standard dose of alcohol. They then remained in our laboratory for 4 hours and completed cognitive testing using the NIH toolbox Cognitive Battery, breath alcohol level measurements and self-reported intoxication ratings (using the The Biphasic Alcohol Effects Scale [BAES] and the The Subjective Effects of Alcohol Scale [SEAS]) and reported their craving levels using the Alcohol Urge Questionnaire (AUQ) every 30 minutes. They also provided 3 blood samples to measure blood-CBD levels at each session (prior to receiving the CBD, 25 minutes post-CBD ingestion and again 60 minutes later). Study sessions were separated by at least one week.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Fort Collins, Colorado, United States, 80523
- Colorado State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 21-60 years old
- able to provide consent
- willing to consume CBD during the study
- report heavy drinking (>5 drinks [>4 for women] per occasion on at least 5 days/month in the past 3 months)
- not cannabis/CBD naive (i.e. THC or CBD use at least once in the past year), do not use cannabis regularly (i.e., less than monthly over past year), and no past-month cannabis use.
Exclusion Criteria:
- a regular or recent cannabis user (i.e. they used cannabis more often than monthly during the past year or used cannabis in the past month)
- were seeking treatment a substance use disorder (SUD) including AUD, taking medications to treat bipolar or psychotic disorders
- using nicotine every day
- taking blood thinning medications
- reported having a major medical condition contraindicating alcohol or CBD use (e.g., liver disease or heart disease)
- reported current suicidality
- met criteria for psychotic disorder, bipolar disorder or a current major depressive episode,
- reported using illicit drugs in the 30 days prior to beginning the study or tested positive for any illicit drugs
- were pregnant, breastfeeding or trying to become pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 200mg Cannabidiol
A single dose of 200mg commercially available (product code T-L-A-5) water-soluble solution supplied by Caliper Foods, to be consumed orally (mixed with water).
|
200mg cannabidiol administered in the laboratory prior to a standard dose of alcohol. The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment). |
Experimental: 30mg Cannabidiol
A single dose of 30mg commercially available (product code T-L-A-5) water-soluble solution supplied by Caliper Foods, to be consumed orally (mixed with water).
|
30mg cannabidiol administered in the laboratory prior to a standard dose of alcohol. The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment). |
Placebo Comparator: Placebo
A single dose of water-soluble Placebo solution supplied by Caliper Foods, to be consumed orally (mixed with water).
|
Placebo administered in the laboratory prior to a standard dose of alcohol. The placebo was made up for the study and contained reverse-osmosis water, gum arabic, MCT (Medium Chain Triglyceride) oil, citric acid, plus the addition of a natural food color, used at <0.1%. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biphasic Effects of Alcohol (BAES)--Stimulation Subscale
Time Frame: At each of the three study sessions, BAES stimulation is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
BAES stimulation will be measured by self-report repeatedly during the experimental session.
The total score on the stimulation subscale ranges from 0-70 where higher is more stimulated.
|
At each of the three study sessions, BAES stimulation is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Biphasic Effects of Alcohol--Sedation Subscale
Time Frame: At each of the three study session, BAES sedation is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
BAES sedation will be measured by self-report repeatedly during the experimental session.
The total score on the sedation subscale ranges from 0-70 where higher is more sedated
|
At each of the three study session, BAES sedation is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Alcohol Urge Questionnaire (AUQ
Time Frame: t each of the three study sessions, AUQ is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
The AUQ is a self-report measure of urge for alcohol and has been validated for real-time assessment of alcohol craving in the laboratory.
The total score on the measure ranges from 0-48 where higher is worse
|
t each of the three study sessions, AUQ is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Subjective Effects of Alcohol Scale (SEAS)--High Arousal Positive Subscale
Time Frame: At each of the three study session, SEAS is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Subjective Effects of Alcohol Scale (SEAS) is a standard self-report measure for assessing subjective mood responses to alcohol.
The SEAS includes 14 items with response option that range from 1-10.
The high arousal positive subscale is a combination of four items from this scale.
|
At each of the three study session, SEAS is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Subjective Effects of Alcohol Scale (SEAS)--Low Arousal Positive Subscale
Time Frame: At each of the three study session, SEAS is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Subjective Effects of Alcohol Scale (SEAS) is a standard self-report measure for assessing subjective mood responses to alcohol.
The SEAS includes 14 items with response option that range from 1-10.
The Low Arousal Positive Subscale is a combination of four items from this scale
|
At each of the three study session, SEAS is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Flanker Inhibitory Control and Attention Task (NIH Toolbox)
Time Frame: At each of the three study session, the Flanker Inhibitory Control and Attention Task is administered at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
The Flanker task measures both a participant's attention and inhibitory control.
The test requires the participant to focus on a given stimulus while inhibiting attention to stimuli flanking it.
|
At each of the three study session, the Flanker Inhibitory Control and Attention Task is administered at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Breath Alcohol Concentration (BrAC)
Time Frame: At each of the three study sessions, BrAC is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)
|
Breath alcohol level will be measured using a breathalyzer repeatedly during the experimental session
|
At each of the three study sessions, BrAC is measured at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DRUID Psychomotor Battery
Time Frame: At each of the three study session, DRUID is administered at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
The DRUID is a mobile app that tests for cognitive and motor impairment, and has been shown to detect impairment related to alcohol and cannabis use.
total score ranges from 0-100 where higher is worse.
|
At each of the three study session, DRUID is administered at baseline (pre ingestion) and again every 30 minutes post ingestion (9 measures)]
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1903
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingAlcohol Use Disorder (AUD)Germany
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompletedAlcohol Use Disorder (AUD)Uganda
-
University Hospital, Basel, SwitzerlandSolidarMedRecruitingAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateLesotho
Clinical Trials on 200mg Cannabidiol oral solution
-
The Methodist Hospital Research InstituteRecruitingRotator Cuff Injuries | Shoulder OsteoarthritisUnited States
-
INSYS Therapeutics IncWithdrawn
-
INSYS Therapeutics IncWithdrawn
-
Radius Pharmaceuticals, Inc.TerminatedChildhood Absence EpilepsyUnited States
-
INSYS Therapeutics IncTerminatedSpasms, InfantileUnited States
-
MultiCare Health System Research InstituteNo longer availableRefractory Epilepsy
-
Radius Pharmaceuticals, Inc.Benuvia Therapeutics Inc.TerminatedChildhood Absence EpilepsyUnited States
-
Meyer Children's Hospital IRCCSNot yet recruitingEpilepsy | Rare Diseases
-
Radius Pharmaceuticals, Inc.Benuvia Therapeutics Inc.TerminatedPrader-Willi SyndromeUnited States
-
INSYS Therapeutics IncCompleted